Migration inhibitory factor in serum as a tumor marker for prostate, bladder, breast, ovarian, kidney, pancreatic and lung cancer and for diagnosis of endometriosis

Macrophage migration inhibitory factor (MIF) has been found to be overexpressed in blood of individuals having various cancers, including prostate, PIN, lung, breast, ovary, kidney, pancreatic and bladder, as well as inflammatory diseases and endometriosis. Normal levels of MIF in serum of males and females without these cancers have been quantified via immunoassay. MIF can be used as a diagnostic tool either by itself or as an adjunct to or in combination with to conventional diagnostic tests.